298 related articles for article (PubMed ID: 30725387)
1. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
4. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
5. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.
Esin E; Ergen A; Cankurtaran M; Yavuz BB; Halil M; Ulger Z; Yeşil Y; Kuyumcu ME; Ozcan M; Cankurtaran E; Ariogul S
Aging Ment Health; 2015; 19(3):217-23. PubMed ID: 25555041
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
8. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Kobayashi S; Ikeda K; Miyata K
Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
[TBL] [Abstract][Full Text] [Related]
9. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
[TBL] [Abstract][Full Text] [Related]
11. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
Todorova A; Vonderheid-Guth B; Dimpfel W
J Clin Pharmacol; 2001 Jun; 41(6):636-44. PubMed ID: 11402632
[TBL] [Abstract][Full Text] [Related]
12. Update on drugs for overactive bladder syndrome.
Drug Ther Bull; 2007 Jun; 45(6):44-8. PubMed ID: 17583229
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
14. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Michel MC; Hegde SS
Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):79-85. PubMed ID: 17021853
[TBL] [Abstract][Full Text] [Related]
15. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the effect of three newly approved overactive bladder syndrome treating agents on parotid and submandibular salivary glands: Modulation of CXCL10 expression.
Aboulhoda BE; Ali EN
Acta Histochem; 2018 Apr; 120(3):269-281. PubMed ID: 29496263
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
18. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of tolterodine on human isolated urinary bladder.
Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
